Launch of Fibrx Therapeutics, a Company Focused on Fibrosis

Skye Bioscience (SKYE) and Redx Pharma have merged to officially launch Fibrx Therapeutics, a Nasdaq-listed company. This merger follows Skye's decision to discontinue the development of Nimacimab, an obesity treatment candidate in Phase 2a clinical trials, as part of a broader business restructuring. The new company will focus on maximizing synergies and accelerating development by combining the fibrosis-related research assets of both companies. In particular, Skye shareholders will be granted a contingent value right (CVR) that allows them to receive 90% of the net profits upon the commercialization of Nimacimab, mitigating risk.

Innovative New Drug RXC008 Enters Phase 2 Clinical Trials

The core pipeline of the newly launched Fibrx Therapeutics is RXC008, a gastrointestinal-localized, pan-ROCK (Rho-associated coiled-coil kinase) inhibitor. This drug is designed to act locally in the intestine, cleverly avoiding the common side effect of hypotension associated with existing ROCK inhibitors. It is currently preparing to enter Phase 2 clinical trials for the treatment of fibrostenotic Crohn's disease and has already been granted Fast Track designation by the U.S. Food and Drug Administration (FDA), demonstrating its development potential. The company aims to initiate Phase 2 trials in the second half of 2026 and obtain topline data in the second half of 2028.

Large Unmet Need in the Fibrostenotic Crohn's Disease Market

The global Crohn's disease market is estimated to be worth $12 billion to $18 billion (USD 12B~18B), but there are currently no approved anti-fibrotic treatments that directly address fibrosis. Patients currently rely on biologic agents to control inflammation, or they must undergo surgical resection or endoscopic balloon dilatation to treat severe strictures. RXC008 targets fibrosis itself, the root cause of the disease, and has the potential to become a first-in-class treatment that can be used alone or in combination with existing standard treatments to prevent long-term organ damage. Given the large unmet need in the market, it is expected to enjoy a dominant position if the clinical trials are successful.

Strong Financial Foundation with $125 Million in Funding

Fibrx secures a strong financial foundation through a large-scale new financing of approximately $125 million (USD 125M) in conjunction with the merger. This financing consists of a $67.9 million PIPE (private investment in public equity), a $36 million Redx Series A, and up to $22 million in committed financing. This funding will provide Fibrx with the financial resources to independently conduct research and development and operations until 2029, without the need for external funding. This will minimize financial risks that may arise during the Phase 2 trials and create an environment where the company can focus on research.

A Strategic Combination for Biotech Survival

This merger can serve as a successful model for the pipeline restructuring and asset combination strategies that are emerging in the biotech venture industry. Skye has revived its value as a listed company by combining it with Redx's promising assets, and Redx, which was previously a private company, has taken a win-win approach by directly entering the Nasdaq market without going through a complex initial public offering (IPO). Compared to competing pipelines such as Agomab's ALK5 inhibitor AGMB-129, it has a unique mechanism of action and ample cash reserves, giving it a competitive advantage. Industry experts believe that this will be a positive signal for increased M&A activity among other small and medium-sized biotech companies in the future.